Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 92Breast 21Genitourinary 9Gastrointestinal 8Classical hematology 5Thoracic 3Sarcoma 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Fanconi Anemia, Complementation Group D1 9Ovarian Neoplasms 5Breast Neoplasms 5Prostatic Neoplasms 2Triple Negative Breast Neoplasms 1Thrombocytosis 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Fanconi Anemia, Complementation Group N 1Blast Crisis 1Anemia 1

Interventions

olaparib 5stinging nettle lectin 1peppermint oil 1niraparib 1liposomal doxorubicin 1ferrous fumarate 1apixaban 1angiotensin I (1-7) 1Tretinoin 1Trabectedin 1Surveys and Questionnaires 1Rivaroxaban 1Pharmacokinetics 1Heparin, Low-Molecular-Weight 1Genetic Counseling 1Gemcitabine 1Ferric Oxide, Saccharated 1Epoetin Alfa 1Demography 1Data Collection 1Darbepoetin alfa 1Counseling 1Cognitive Behavioral Therapy 1Carboplatin 1Aspirin 1Anticoagulants 1ALT-836 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Ovarian Neoplasms × olaparib × Classical hematology × Clear all
NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

AstraZeneca

Phase 2 Completed
265 enrolled 25 charts 1 FDA
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

AstraZeneca

Phase 1 Completed
98 enrolled
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

AstraZeneca

Phase 2 Completed
97 enrolled 22 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02418624 2019-01-16

REVIVAL

The Netherlands Cancer Institute

Phase 1 Completed
25 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT00494442 2018-08-01

ICEBERG 2

AstraZeneca

Phase 2 Completed
58 enrolled 13 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡